Electrophysiology Catheters Market Size to Grow by USD 2.24 Billion from 2022-2027

Abbott Laboratories, Acutus Medical Inc., and Johnson and Johnson are some of the major companies in the market - Technavio

The Electrophysiology Catheters Market size is expected to grow by USD 2.24 billion, accelerating at a CAGR of 8.73% during the forecast period, according to Technavio Research. Companies are implementing various strategies like forming partnerships, mergers, expanding into new areas, and launching new products to improve their market position. The report also offers detailed analyses of the market’s competitive landscape, featuring information on leading companies including Abbott Laboratories, Acutus Medical Inc., AngioDynamics Inc., APT Medical, AtriCure Inc., BIOTRONIK SE and Co. KG, Boston Scientific Corp., CardioFocus Inc., CathRx Pty Ltd., Japan Lifeline Co. Ltd., Johnson and Johnson, Koninklijke Philips N.V., Medtronic Plc, Merit Medical Systems Inc., MicroPort Scientific Corp., Millar Inc., Nihon Kohden Corp., OSYPKA AG, Siemens Healthineers AG, Stereotaxis Inc. and Stryker Corp. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.

Electrophysiology Catheters Market: Company Profile

Abbott Laboratories: The company offers electrophysiology catheters such as Advisor HD grid sensor-enabled mapping catheter.

To gain access to more company profiles available with Technavio, buy the report

Electrophysiology Catheters Market: Segmentation Analysis

The market is segmented by End-user (Hospitals and cardiac centers and ASCs), Product (Ablation catheters and Diagnostic catheters), and Geography (North America, Europe, Asia, and Rest of World (ROW)).

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. Download the free sample report here

Electrophysiology Catheters Market: Geographical Analysis

It is projected that North America will play a substantial role, contributing approximately 38% to the global market’s growth during the forecast period. In developed nations within the region, notably the United States and Canada, the presence of well-established healthcare facilities is driving increased demand for balloon catheters and cardiac ablation catheters.

Electrophysiology Catheters Market: Driver, Trend & Challenge

Driver – The growth of the electrophysiology catheter market is driven by the increasing incidence of cardiac diseases and the expansion of insurance providers. Heart disease prevalence is rising globally, including valvular heart disease, especially due to increased life expectancy. High blood pressure is a leading cause of conditions like atrial fibrillation, which can lead to strokes or heart attacks. Additionally, healthcare options like the European Health Insurance Card (EHIC) in the EU and medical screenings provided by the UK’s National Health Service (NHS) further contribute to market growth.

Trends – The use of remote navigation in cardiac mapping and imaging is the key trend in the market.

Challenges – A stringent regulatory framework is a challenge that affects the growth of the market.

Identify more information on key trends, drivers, and challenges of the market. Download to gain access to this information

What are the key data covered in this electrophysiology catheters market report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the electrophysiology catheters market between 2022 and 2027.
  • Precise estimation of the electrophysiology catheters market size and its contribution to the market in focus on the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of electrophysiology catheters market vendors.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.